GSK and Genmab Receive CHMP Positive Opinion for Arzerra(tm) in Combination with Chlorambucil or Bendamustine as a First-line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL) Who Are Not Eligible for Fludarabin